Fusion proteins comprising P3 of bacteriophage
AssigneeProclara Biosciences, Inc.
InventorsRajaraman Krishnan, Richard Fisher
Life of this patent
Estimating the term…
Abstract
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
Claims22
A nucleic acid sequence encoding a fusion protein comprising an amyloid binding fragment of g3p and an Fc fragment of an immunoglobulin, wherein the fusion protein comprises:
- (a) amino acids 21-506 of SEQ ID NO:9;
- (b) amino acids 22-506 of SEQ ID NO:9;
- (c) amino acids 23-506 of SEQ ID NO:9;
- (d) amino acids 21-505 of SEQ ID NO:9;
- (e) amino acids 22-505 of SEQ ID NO:9;
- (f) amino acids 23-505 of SEQ ID NO:9;
- (g) amino acids 21-506 of SEQ ID NO:11;
- (h) amino acids 22-506 of SEQ ID NO:11;
- (i) amino acids 23-506 of SEQ ID NO:11;
- (j) amino acids 21-505 of SEQ ID NO:11;
- (k) amino acids 22-505 of SEQ ID NO:11;
- (l) amino acids 23-505 of SEQ ID NO:11;
- (m) amino acids 21-509 of SEQ ID NO:13;
- (n) amino acids 22-509 of SEQ ID NO:13;
- (o) amino acids 23-509 of SEQ ID NO:13;
- (p) amino acids 21-508 of SEQ ID NO:13;
- (q) amino acids 22-508 of SEQ ID NO:13;
- (r) amino acids 23-508 of SEQ ID NO:13;
- (s) amino acids 21-528 of SEQ ID NO:31;
- (t) amino acids 22-528 of SEQ ID NO:31;
- (u) amino acids 23-528 of SEQ ID NO:31;
- (v) amino acids 21-527 of SEQ ID NO:31;
- (w) amino acids 22-527 of SEQ ID NO:31;
- (x) amino acids 23-527 of SEQ ID NO:31;
- or
- (y) a mutant or variant that is at least 95% identical to the amino acid sequence of any one of (a)-(x) and is capable of binding to amyloid.
A nucleic acid sequence encoding a fusion protein comprising an amyloid binding fragment of g3p, wherein the fusion protein comprises:
- (a) amino acids 21-238 of SEQ ID NO:9;
- (b) amino acids 22-238 of SEQ ID NO:9;
- (c) amino acids 23-238 of SEQ ID NO:9;
- (d) amino acids 21-238 of SEQ ID NO:11;
- (e) amino acids 22-238 of SEQ ID NO:11;
- (f) amino acids 23-238 of SEQ ID NO:11;
- (g) amino acids 21-238 of SEQ ID NO:13;
- (h) amino acids 22-238 of SEQ ID NO:13;
- (i) amino acids 23-238 of SEQ ID NO:13;
- (j) amino acids 21-296 of SEQ ID NO:31;
- (k) amino adds 22-296 of SEQ ID NO:31;
- (l) amino acids 23-296 of SEQ ID NO:31;
- or
- (m) a mutant or variant that is at least 95% identical to the amino acid sequence of any one of (a)-(l) and is capable of binding to amyloid.
A method of treating a patient for a disease or condition by administering to the patient a fusion protein comprising an amyloid binding fragment of g3p and an Fc fragment of an immunoglobulin, wherein the fusion protein comprises:
- (a) amino acids 21-506 of SEQ ID NO:9;
- (b) amino acids 22-506 of SEQ ID NO:9;
- (c) amino acids 23-506 of SEQ ID NO:9;
- (d) amino acids 21-505 of SEQ ID NO:9;
- (e) amino acids 22-505 of SEQ ID NO:9;
- (f) amino acids 23-505 of SEQ ID NO:9;
- (g) amino acids 21-506 of SEQ ID NO:11;
- (h) amino acids 22-506 of SEQ ID NO:11;
- (i) amino acids 23-506 of SEQ ID NO:11;
- (j) amino acids 21-505 of SEQ ID NO:11;
- (k) amino acids 22-505 of SEQ ID NO:11;
- (l) amino acids 23-505 of SEQ ID NO:11;
- (m) amino acids 21-509 of SEQ ID NO:13;
- (n) amino acids 22-509 of SEQ ID NO:13;
- (o) amino acids 23-509 of SEQ ID NO:13;
- (p) amino acids 21-508 of SEQ ID NO:13;
- (q) amino acids 22-508 of SEQ ID NO:13;
- (r) amino acids 23-508 of SEQ ID NO:13;
- (s) amino acids 21-528 of SEQ ID NO:31;
- (t) amino acids 22-528 of SEQ ID NO:31;
- (u) amino acids 23-528 of SEQ ID NO:31;
- (v) amino acids 21-527 of SEQ ID NO:31;
- (w) amino acids 22-527 of SEQ ID NO:31;
- (x) amino acids 23-527 of SEQ ID NO:31;
- or
- (y) a mutant or variant that is at least 95% identical to the amino acid sequence of any one of (a)-(x) and is capable of binding to amyloid;
- and
- wherein the disease or condition is selected from SAA amyloidosis, cystatin C, hereditary Icelandic syndrome, senility, multiple myeloma, kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia (FFI), scrapie, amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA1, SCA3, SCA6, or SCA7), Huntington's disease, dentatorubral-pallidoluysian atrophy, spinal and bulbar muscular atrophy, hereditary cerebral amyloid angiopathy, familial amyloidosis, frontotemporal lobe dementia, British/Danish dementia, and familial encephalopathy.
Dependencies are inferred from the claim text.